Tay- Sachs disease is an autosomal recessively inherited lysosomal storage disorder caused by mutations on the HEXA gene encoding α-subunit of βHexosaminidase A enzyme. The enzyme catalyzes GM2 to GM3 conversion but when it is deficient the GM2 degradation is interrupted and GM2 ganglioside is progressively accumulated especially in neurons. Progressive accumulation of GM2 causes increasing death of neurons, disruption in mental and motor functions and eventually death at 2-4 years of age. The Hexa-/- Tay-Sachs model was normal thanks to a bypass mechanism mediated by Neurominidase3. It was determined that Hexa-/-Neu3-/- mice mimicked the neuropathologic and clinical phenotype of the Tay-Sachs disease. Previously we showed GM2 accumulation in Hexa-/-Neu3-/- Tay Sachs disease mouse model triggers release of proinflammatory cytokines, microgliosis, astrogliosis consequently activation of inflammatory cascades as well as oxidative stress. These inflammatory events contribute to neurodegeneration observed in the disease pathology. In Sandhoff Disease mouse model it was shown that astrocytes express adenosine A2A receptors which induces ccl2 chemokine overexpression. A2A receptor antagonist istradefylline treatment reduces microglial activation and ccl2 expression in Sandhoff mice. In this study; A2A receptor antagonist istradefylline treatment was applied to Tay Sachs disease mouse model and whether this treatment would alleviate the neuroinflammation and redox imbalance; and prolong the lifespan was investigated by molecular biological and behavioural analyses. Modulation of ccl2 expression by istradefylline was used as potential therapeutic target to slow down Tay Sachs disease mouse model